Conference Rescheduled to June 28, 2025
Program Overview
The 18th Annual Diabetes Symposium is a 1-day virtual course. The purpose of this symposium is to update health care providers with state-of-the-art information regarding evaluation and treatment of patients with diabetes. Information is constantly evolving, and physicians lack knowledge related to the most effective treatments for patients with diabetes as well as the role of newer treatments in preventing cardiovascular and renal complications of diabetes as per the guidelines published by the ADA. In addition, they should understand the use of SGLT2 inhibitors in patients with diabetes and heart failure, newer strategies for weight loss in obese patient, and the management of diabetes in hospitalized patients including the use of continuous glucose monitors. The symposium will also address new diabetes technology for insulin delivery and understand the advantages (e.g., reduction in hypoglycemia) with newer technology and insulin formulations. Physicians should effectively identify the adverse effects of diabetes therapies and identify additional practice gaps that should be addressed in the future.
Target Audience
For this symposium, the target audience is endocrinologists, cardiologists, primary care physicians, cardiovascular surgeons, family and general practitioners, nurses, nurse practitioners, dieticians and physician assistants. We will update health care providers with state-of-the-art information regarding evaluation and treatment of patients with diabetes.
Learning Objectives
At the conclusion of this symposium, participants should be able to:
• Describe novel and optimal therapies for treatment of type 2 diabetes.
• Discuss and generate evidence-based treatment strategies for management of type 2 diabetes based on recently published clinical trials regarding cardiovascular and renal outcomes with SGLT-2 inhibitors and GLP-1 receptor agonists.
• Explain comprehensive strategies for cardiovascular risk reduction in type 2 diabetes.
• Describe the role of newer insulins in the management of diabetes.
• Incorporate effective weight reduction treatments in the management of obese patients with type 2 diabetes.
• Develop and implement effective strategies for the management of hyperglycemia in hospitalized patients.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Texas Heart Institute, Baylor St. Luke’s Medical Center, and Baylor College of Medicine. The Texas Heart Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Texas Heart Institute designates this live activity for a maximum of 8.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Successful completion is a passing grade of 70% on the assessment in the CME evaluation.
The deadline to complete the MOC section of the CME evaluation is 2 weeks after the day of the symposium.
Nursing and Dietician credits will be offered.
